230 related articles for article (PubMed ID: 19949921)
1. Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.
Calcagno AM; Ambudkar SV
Methods Mol Biol; 2010; 596():77-93. PubMed ID: 19949921
[TBL] [Abstract][Full Text] [Related]
2. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
5. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
[TBL] [Abstract][Full Text] [Related]
6. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
9. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).
Heffeter P; Jakupec MA; Körner W; Chiba P; Pirker C; Dornetshuber R; Elbling L; Sutterlüty H; Micksche M; Keppler BK; Berger W
Biochem Pharmacol; 2007 Jun; 73(12):1873-86. PubMed ID: 17445775
[TBL] [Abstract][Full Text] [Related]
10. Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development.
Moinul M; Amin SA; Jha T; Gayen S
Eur J Med Chem; 2022 Nov; 241():114628. PubMed ID: 35944339
[TBL] [Abstract][Full Text] [Related]
11. Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma.
Chen KG; Valencia JC; Gillet JP; Hearing VJ; Gottesman MM
Pigment Cell Melanoma Res; 2009 Dec; 22(6):740-9. PubMed ID: 19725928
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
13. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
14. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.
Michaelis M; Rothweiler F; Nerreter T; van Rikxoort M; Zehner R; Dirks WG; Wiese M; Cinatl J
BMC Res Notes; 2014 Oct; 7():710. PubMed ID: 25300205
[TBL] [Abstract][Full Text] [Related]
15. Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.
Wu ZX; Teng QX; Cai CY; Wang JQ; Lei ZN; Yang Y; Fan YF; Zhang JY; Li J; Chen ZS
Biochem Pharmacol; 2019 Aug; 166():120-127. PubMed ID: 31078601
[TBL] [Abstract][Full Text] [Related]
16. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
Schneiderman RS; Shmueli E; Kirson ED; Palti Y
BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
[TBL] [Abstract][Full Text] [Related]
17. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
19. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
20. Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance.
Li S; Zhang W; Yin X; Xing S; Xie HQ; Cao Z; Zhao B
Anticancer Agents Med Chem; 2015; 15(4):423-32. PubMed ID: 25929575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
